December 9, 2016

December 09, 2016

Novel Compound Targets Anemia in MDS
MedPage Today – Dec. 9
In a phase II dose-ranging study, sotatercept (also known as ACE-011) led to hematological improvement in nearly half of 54 evaluable patients who did not respond to erythropoiesis-stimulating agents, according to Rami Komrokji, MD, of Moffitt Cancer Center in Tampa, Fla., and colleagues.

'Alive, Dead, or Somewhere in Between?' What We Heard This Week
MedPage Today – Dec. 9
"Induction with CPX-351 was associated with lower induction-related morbidity and mortality, which means that patients may be transplanted in better condition. Patients may also attain better disease control, leading to more patients being transplanted in complete remission." -- Jeffrey Lancet, MD, of Moffitt Cancer Center in Tampa, Fla., on data from a randomized trial of induction therapy with an investigational liposome-encapsulated chemotherapy prior to allogeneic stem cell transplant

Chemo Plus Veliparib Improves Responses in BRCA-Mutant Breast Cancer
Cancer Network – Dec. 9
“Existing homologous recombination DNA damage repair defects in tumors with BRCA1/2mutations make them particularly sensitive to PARP inhibitors, which interfere with DNA damage repair,” said Heather S. Han, MD, of the Moffitt Cancer Center in Tampa, Florida. She presented the new study at the San Antonio Breast Cancer Symposium (SABCS), held December 6–10, and spoke during a press conference on Wednesday.

AbbVie Pursues Phase III Veliparib Study in BRCA Mutated Breast Cancer After Phase II Survival Trend
GenomeWeb – Dec. 8
In the Phase II trial funded by AbbVie, researchers led by Moffitt Cancer Center's Hyo Sook Han enrolled nearly 300 locally recurrent or metastatic breast cancer patients with BRCA1/2 mutations as determined by Myriad Genetics' BRACAnalysis test. 

Veliparib Safe in Combination With Carboplatin and Paclitaxel for BRCA1/2-associated Breast Cancer
Cancer Therapy Advisor – Dec. 8
Veliparib did not affect the safety profile, frequency of interruption, dose reduction rate, or discontinuation rate, reported Hyo-Sook Han, MD, of the Moffitt Cancer Center in Tampa, Florida.

Adding Veliparib to chemotherapy improved response rates among patients with BRCA-mutant breast cancer
MedicalXpress.com – Dec. 8
"People who inherit mutations in BRCA1 or BRCA2 are at increased risk of developing various malignancies, including breast cancer and ovarian cancer," said Heather S. Han, MD, associate member at the Moffitt Cancer Center in Tampa, Florida.

Sunburn – What’s hot in Florida Politics
Saintpetersblog.com – Dec. 8
Rubio and Nelson both applauded passage by the U.S. Senate of a bill that heads off potential cuts in cancer research at Moffitt Cancer Center in Tampa and the University of Miami’s Sylvester Comprehensive Cancer Center. The Senate approved H.R. 34, entitled the “21st Century Cures Act,” by a 94-5 vote.

Results Mixed for Veliparib Regimen in BRCA+ Breast Cancer
Targeted Oncology – Dec. 7
“Although the improvements in progression-free and overall survival were not statistically significant, the study supports further investigation of veliparib in combination with chemotherapy as a potential treatment for this group of patient," lead study author Hyo Sook Han, MD, associate member at Moffitt Cancer Center, said when presenting the results.

Hillsborough County reflects on 75th anniversary of Pearl Harbor
WFLA – Dec. 7
Moffitt Cancer Center patient George Kondas shares his experience at Pearl Harbor 75 years ago.

Local Pearl Harbor survivor recounts attack on 75th anniversary
ABC Action News – Dec. 7
Moffitt Cancer Center patient George Kondas shares his experience at Pearl Harbor 75 years ago.

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk AML Patients
OncologyTube – Dec. 7
Jeffrey E. Lancet, MD of Moffitt Cancer Center presents Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial at the 58th ASH Annual Meeting in San Diego, CA.

Breast cancer patient talks about being mistreated by TSA workers
WTSP – Nov. 7
Mark Honor is a Physicians Assistant at Moffitt Cancer Center here in Tampa.  He deals with patients like Denise every day and was appalled at the video. "Just being a cancer patient out in public not feeling well, especially with the nerve sensations of peripheral neuropathy, wearing a wig being out in general population, that's enough to make you feel uncomfortable. Mix that with somebody wanting to pat you down and inspect you. That's got to be a horrifying experience for sure."

Veliparib Regimen Nears 80% Response Rate in BRCA+ Breast Cancer
OncLive – Dec. 7
“The addition of veliparib to carboplatin/paclitaxel resulted in trends toward improved progression-free survival (PFS) and overall survival (OS), and a significant increase in the overall response rate (ORR),” lead study author Hyo Sook Han, MD, associate member at Moffitt Cancer Center, said when presenting the results at the 2016 San Antonio Breast Cancer Symposium.

SABCS: Veliparib Fails in Phase II Breast Cancer Study
MedPage Today – Dec. 7
Progression-free survival was 12.3 months with the combination of placebo plus carboplatin and paclitaxel and 14.1 months when veliparib was added (P=0.231), reported Heather Sook Han, MD, of Moffitt Cancer Center in Tampa, Fla.

Tampa Pearl Harbor survivor: ‘can see it exactly today as it was’
Bay News 9 – Dec. 7
Doctors removed one of his lungs because they weren’t sure how far the cancer had spread. After winning the battle against lung cancer, doctors at Moffitt Cancer Center in Tampa diagnosed him with prostate cancer. Again he fought with bravery and beat the disease.

KTE-C19 Treatment Shows Impressive Responses in Aggressive Lymphomas
Targeted Oncology – Dec. 6
"ZUMA-1 is the first multicenter CD19 CAR study in refractory DLBCL, PMBCL, and TFL," commented lead investigator Frederick L. Locke, MD, Department of Blood and Marrow Transplantation, Moffitt Cancer Center.

KTE-C19 Response Rates Spark FDA Submission for Aggressive Lymphomas
OncLive – Dec. 6
"ZUMA-1 is the first multicenter CD19 CAR study in refractory DLBCL, PMBCL, and TFL," commented lead investigator Frederick L. Locke, MD, Department of Blood and Marrow Transplantation, Moffitt Cancer Center. "The trial is ongoing at 22 sites and there has been a 100% manufacturing success rate."

Can a Regret-Based Decision Model Lead to Higher Patient Satisfaction Among Terminally Ill Patients?
ASH Clinical News – Dec. 5
“The decision process in [these] situations is heavily affected by emotions, chief among them is regret,” the researchers, led by Benjamin Djulbegovic, MD, PhD, from the Departments of Hematology and Health Outcomes & Behavior at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, said, explaining the choice to focus on regret in their decision model. 

Older AML Patients Survive Longer With New Chemotherapy Delivery Method
Cancer Network – Dec. 4
CPX‐351 may provide a bridge to successful transplant in a poor‐risk subgroup of AML patients, said lead author Jeffrey E. Lancet, MD, of the Moffitt Cancer Center in Tampa, Florida, at a press briefing. “Some 20% or less of these patients goes on to transplant. We hope that more successful therapy and less toxicity will allow more patients to get to allotransplant,” he said.

Survival Improves When Older Patients With AML Receive CPX-351 Before Transplant
OncLive – Dec. 4
Jeffrey E. Lancet, MD, senior member and chief of the Leukemia/Myelodysplasia Program at the Moffitt Cancer Center, presented this new subgroup analysis during a press conference at the 2016 ASH Annual Meeting.

Large granular lymphocyte proliferations in MDS
eCancer – Dec. 4
Dr Roe speaks with ecancertv at ASH 2016 about genotyping and treatment outcomes for patients with myelodysplastic syndrome with T cell large granular lymphocyte proliferations (LGL)

Survival Boost With Liposomal Tx in Older AML Patients
MedPage Today – Dec. 4
The results added to a previously reported survival benefit of older patients with AML treated with CPX-351, a majority of whom did not undergo ASCT, Jeffrey Lancet, MD, of Moffitt Cancer Center in Tampa, Fla., reported here at the American Society of Hematology annual meeting.

CPX-351 Before Transplant Improves Survival for Older Patients With AML
Targeted Oncology – Dec. 3
Jeffrey E. Lancet, MD, senior member and chief of the Leukemia/Myelodysplasia Program at the Moffitt Cancer Center, presented this new subgroup analysis during a press conference at the 2016 ASH Annual Meeting.

Hudson’s Furniture Donates to Moffitt Cancer Center
WTSP – Dec. 2
Hudson's Furniture donated more than $7,000 to the Moffitt Cancer Center that was raised during Breast Cancer Awareness month in October.

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.